BeyondSpring, Inc.

The momentum for this stock is not very good. BeyondSpring, Inc. is not a good value stock. BeyondSpring, Inc. is a mediocre stock to choose.
Log in to see more information.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies...
BYSI Fundamental Data by TradingView

News

BeyondSpring announces Dublin-3 final phase 3 efficacy data
BeyondSpring announces Dublin-3 final phase 3 efficacy data

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-

Globe Newswire - Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC...\n more…

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

Globe Newswire FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ( BeyondSpring or the Company ), a clinical-stage global biopharmaceutical company focused on developing...\n more…

BeyondSpring First Half 2024 Earnings: US$0.19 loss per share (vs US$0.33 loss in 1H 2023)
BeyondSpring First Half 2024 Earnings: US$0.19 loss per share (vs US$0.33 loss in 1H 2023)

Simply Wall St BeyondSpring ( NASDAQ:BYSI ) First Half 2024 Results Key Financial Results Revenue: US$1.00m (up 14% from 1H 2023). Net...\n more…

BeyondSpring Inc. Reports Mid-Year Financials
BeyondSpring Inc. Reports Mid-Year Financials

TipRanks Financial Blog Beyondspring (BYSI) has released an update. BeyondSpring Inc., a foreign private issuer, has reported its financial results for the first half of 2024, showing tota...\n more…

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indication
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indication

Globe Newswire SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by EisaiThe SEED-Eisai Research Collaboration leverages Eisai's leading expertise in neurodegeneration and...\n more…